药物治疗胆汁淤积性肝病的研究进展  

Research Progress on Pharmacological Treatment for Cholestatic Liver Disease

作　　者：金浩源 王德强[1] 李浩天 贾辰昊 周秉昌 

机构地区：[1]内蒙古科技大学包头医学院第一附属医院肝胆胰脾外科,内蒙古 包头

出　　处：《临床个性化医学》2024年第4期2248-2255,共8页Journal of Clinical Personalized Medicine

基　　金：包头医学院青年科技人才发展计划任务书(编号:BYJJ-DXK 2022041)。

摘　　要：胆汁淤积性肝病是指由各种原因导致胆汁形成、分泌、排泄异常,从而引起肝脏发生病变。目前,胆汁淤积性肝病治疗主要通过熊去氧胆酸及法尼醇X受体激动剂奥贝胆酸。近些年发现成纤维细胞生长因子-19和过氧化物酶体增殖物激活受体激动剂也在治疗中发挥作用。此外,国内外多项实验研究证实顶端钠依赖性胆酸转运体抑制剂、免疫治疗和中医治疗也是治疗胆汁淤积性肝病的潜在方法。本文旨在对胆汁淤积性肝病及其治疗药物的研究进展进行阐述,为治疗此类疾病的方向提供更多的参考依据。Cholestatic liver disease is a condition in which bile formation, secretion, and excretion are abnormal for various reasons, resulting in liver lesions. Currently, cholestatic liver disease is treated mainly by ursodeoxycholic acid and the farnesol X receptor agonist obeticholic acid. In recent years, fibroblast growth factor-19 and peroxisome proliferator-activated receptor agonists have also been found to play a role in the treatment. In addition, several experimental studies at home and abroad have confirmed that apical sodium-dependent bile acid transporter inhibitors, immunotherapy, and traditional Chinese medicine therapy are also potential treatments for cholestatic liver disease. The purpose of this paper is to describe the research progress of cholestatic liver disease and its therapeutic drugs and to provide more references for the direction of the treatment of such diseases.

关 键 词：胆汁淤积性肝病 药物治疗 中医治疗 

分 类 号：R57[医药卫生—消化系统]